ArticleMedical science monitor : international medical journal of experimental and clinical research2014
Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Do Protocadherins Show Prognostic Value in the Carcinogenesis of Human Malignant Neoplasms? Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2020Pooled it
- Integrative Machine Learning Framework Revealing TRPM4-Associated Signatures and Identifying SPATA6 as a Potential Biomarker in Prostate Cancer.Journal of Cancer · 2026Article
- The role of Pcdh10 in neurological disease and cancer.Journal of cancer research and clinical oncology · 2023Review
- Cell-free DNA in the management of prostate cancer: Current status and future prospective.Asian journal of urology · 2023Review
- Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms.BMC cancer · 2022Article
- Signature Panel of 11 Methylated mRNAs and 3 Methylated lncRNAs for Prediction of Recurrence-Free Survival in Prostate Cancer Patients.Pharmacogenomics and personalized medicine · 2021Article
- Epigenetic silencing of protocadherin 10 in colorectal cancer.Oncology letters · 2017Article
- Effect ofInternational journal of clinical and experimental pathology · 2017Article
- DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.Molecular diagnosis & therapy · 2016Review
- Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Effect of Cnidium Lactone on Serum Mutant P53 and BCL-2/BAX Expression in Human Prostate Cancer Cells PC-3 Tumor-Bearing BALB/C Nude Mouse Model.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Polymorphisms in NFKB1 and NFKBIA Genes Modulate the Risk of Developing Prostate Cancer among Han Chinese.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- PCDH10, a novel p53 transcriptional target in regulating cell migration.Cell cycle (Georgetown, Tex.) · 2015Article
- APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is a common malignancy in men, and inevitably some patients experience biochemical recurrence after radical prostatectomy. To date, there are no reliable predictors for prostate cancer recurrence, and novel predictors are urgently needed. PCDH10 (protocadherin-10) is a novel tumor suppressor gene, which is down-regulated by promoter methylation in prostate cancer. The aim of this study was to evaluate the feasibility of using PCDH10 methylation to predict the biochemical recurrence (BCR) of prostate cancer after radical prostatectomy. MATERIAL/
methodsFresh tissue samples were obtained from 151 patients with primary prostate cancer, and from 34 patients with benign prostatic hyperplasia (BPH) as control. The methylation status of PCDH10 in prostate cancer tissues and controls were examined using methylation-specific PCR (MSP), and then associated with clinicopathological features and BCR-free survival of patients with prostate cancer.
resultsWe found that PCDH10 methylation was detected in 79 (52.3%) patients with prostate cancer, but no methylation was found in controls (P<0.0001). Moreover, PCDH10 methylation was significantly associated with higher preoperative prostate-specific antigen (PSA) level (P <0.0001), higher Gleason Score (P<0.0001), advanced clinical stage (P=0.0002), lymph node metastasis (P=0.0389), angiolymphatic invasion (P=0.0303), and biochemical recurrence (P=0.0068). Moreover, PCDH10 methylation was associated with poor BCR-free survival (P<0.0001), and may be used as an independent predictor of BCR-free survival (P=0.0046).
conclusionsOur results indicate that PCDH10 methylation in prostate cancer tissue is an independent prognostic biomarker of worse BCR-free survival of patients with prostate cancer after radical prostatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.